Paul Meister, executive chairman of inVentiv Health, has been made CEO of the company. Meister is founder and CEO of Liberty Lane Partners, a private equity firm involved in the August 2010 takeover of inVentiv.
From 1991 to 2006 Meister was an executive officer at Fisher Scientific.
Icon has appointed Anthony Priestley as medical director at its clinical pharmacology unit in Manchester, UK. Priestly has previously worked at LCG Bioscience and Serono.
Sheila Ogle has resigned as CEO of patient recruitment specialist ICTS. Ogle has worked at ICTS for eight years and will be replaced by Tom Sturgis, the company’s president.
OSO BioPharmaceuticals Manufacturing has named Craig Mastenbaum as director of new business development for the US West Coast market. Mastenbaum has more than 30 years of manufacturing experience working at Hollister-Stier Laboratories and Chiron.
Erik Yelle has left Warnex Analytical Services. Yelle worked as vice president (VP), operations but has left to pursue other interests. Mark Busgang, president and CEO of the company, will assume Yelle’s responsibilities in the near term.
WaferGen Biosystems has elected Arul Chinnaiyan to its scientific advisory board. Chinnaiyan is a clinical genomics cancer researcher experienced in the use of biomarkers.
Roger Hayes has joined Cetero Research as president, bioanalytical operations. Hayes is a former employee of Schering-Plough and, after the acquisition, Merck & Co with 15 years of experience.
Biopharm Services has appointed Udo Vetter and Nigel Titchener to advise its board of directors on business strategy. Vetter is chairman of the board at Vetter Pharma and a member of the supervisory board at Gerresheimer.
Wolfgang Noe has been named as a senior consultant at BioProcess Technology Consultants. Noe most recently worked as VP, strategic development and technical alliance at Biogen Idec.